Skip to main content
. 2020 Jul 22;9(8):1755. doi: 10.3390/cells9081755

Figure 1.

Figure 1

Clinical outcome associated with FGF14 expression in lung adenocarcinoma (LUAC). (A) mRNA expression analysis of FGF14 in LUAC patients samples (n = 18) compared to non-tumor tissue (NT). (B) Immunohistochemical staining of FGF14 in LUAC and healthy donor tissue samples (n = 3). Scale bar 50 µm. Kaplan–Meier estimate of (C) overall survival (OS) and (D) disease free survival (DFS) among Okayama patients dataset with LUAC that was classified according to the levels of FGF14 mRNA as either high (above the mean value of FGF14 mRNA levels; red) and low (below the mean value of FGF14 mRNA levels; blue). (E) mRNA expression level of FGF14 in LUAC samples from the same study compared with non-tumor tissue. (F) Analysis of FGF14 expression in KRAS mutant vs KRAS non-mutant patients samples and (G) EGFR mutant vs EGFR non-mutant samples. (H) mRNA expression of FGF14 in different lung cancer cell lines e.g., LUAC (A549, H1299, H838, and H1650), LUSC (H226. and H520), lung carcinoma (A427) and large cell lung cancer (H460) compared with primary human bronchial epithelial cells (HBEC). Data obtained from CANCERTOOL (C–G). Data shown as mean+/- standard error of the mean using Student’s t-test. P-values ≤ 0.05 were considered statistically significant for all analyses. ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001.